Development of Insulin-like peptide 5 (INSL5) peptide analogues as novel therapeutics. Insulin-like peptide 5 (INSL5) is a naturally-occurring hormone in the body that likely plays a role in the control of appetite. This project aims to develop new molecules based on INSL5 that could be suitable for use as drugs to treat various appetite-related disorders, such as obesity (where patients eat too much) or anorexia (where patients eat too little).
Intracellular trafficking and function of a recycling receptor which prolongs the serum half-life of novel therapeutic proteins. The life span of recombinant engineered proteins for therapeutic use is a critical factor in their effectiveness, ease of clinical application and cost. This project will exploit interactions with a natural receptor, which prolongs the lifespan of serum proteins, to enhance survival of therapeutic engineered proteins.
Exploiting the lymphatic system for next generation vaccine development . Vaccination is the most successful and cost-effective means of combating infectious diseases. This project will look at how vaccine adjuvants work and will help the development of new vaccines against infections in both animals and man. It will also promote the training of Australian scientists in the field of vaccine research and development.
Grafted peptide constructs - a new platform for delivering stable bioactive peptides. The project will develop a new strategy to overcome the lack of bioavailability of peptides. The project will design an effective drug delivery vehicle and facilitate drug development as highly active peptides will become attractive drug targets.
New technology for the delivery of peptide-based T-cell vaccines for tumour immunotherapy. This project is dedicated to finding simple methods for vaccinating humans and animals against a wide variety of cancers. Should this be achieved millions of Australians will be protected from the devastating consequences of cancer. Consequently there will be great benefits socially, medically and economically.
New stable and specific mimics of T cell epitopes for tumor immunotherapy. This project is dedicated to finding simple methods for vaccinating humans and animals against a wide variety of cancers. Should this be achieved millions of Australians will be protected from the devastating consequences of cancer. Consequently there will be great benefits socially, medically and economically.
Development of novel therapies for the treatment of cancer. Both aging and obesity are significant risk factors for cancer and are becoming a burden on the health care budget. The proposed novel cancer therapy will improve current cancer treatments by enhancing their efficacy, thereby reducing the required dose and minimizing side effects. Such an outcome would not only benefit the well being of the individual but would achieve significant health care cost savings.
Novel green scalable chemical peptide synthesis and enzyme immobilization. The Project aims to address the critical issue of developing green processes for the chemical production of peptides including on an industrial scale. It will use unique, biocompatible solid supports that have been invented by our partner SpheriTech Ltd together with other reagents to allow synthesis to be conducted in water rather than toxic organic solvents. Expected outcomes of the Project include an international part ....Novel green scalable chemical peptide synthesis and enzyme immobilization. The Project aims to address the critical issue of developing green processes for the chemical production of peptides including on an industrial scale. It will use unique, biocompatible solid supports that have been invented by our partner SpheriTech Ltd together with other reagents to allow synthesis to be conducted in water rather than toxic organic solvents. Expected outcomes of the Project include an international partnership in highly efficient environmentally-friendly assembly of peptides and of their analogues by both solid phase synthesis and immobilized enzyme-mediated ligation. The clear benefit will be the first novel, water-based, scalable green synthesis of peptides as biological probes and potential therapeutic agents.Read moreRead less
Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasm ....Modulation of protein folding pathways: a new platform technology for molecular medicine. Misfolding of proteins is becoming recognised as a major cause of inherited disease. We propose to develop a chemical agent that will optimise the folding of alpha1-antitrypsin (AAT), misfolding of which gives rise to inheritable liver and lung disease. This agent will have potential application as a therapy for sufferers of AAT-misfolding disease and for improving the yield of AAT purified from human plasma, which is the current agent used to treat patients with AAT-misfolding disease.Read moreRead less
New insulins for the improved management of diabetes. The prevalence of diabetes has increased dramatically over the past few decades and now this condition is widely considered the world’s fastest growing disease. New insulins with improved pharmacological and storage properties are desperately needed, and this project will work on chemical synthesis enabling designer insulins to be prepared for improved management of diabetes.